Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.

Nallasamy P, Chava S, Verma SS, Mishra S, Gorantla S, Coulter DW, Byrareddy SN, Batra SK, Gupta SC, Challagundla KB.

Semin Cancer Biol. 2018 Oct;52(Pt 2):53-65. doi: 10.1016/j.semcancer.2017.11.009. Epub 2017 Nov 28. Review.

PMID:
29196189
2.

PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.

Melaiu O, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, Furlanello C, Locatelli F, Fruci D.

Clin Cancer Res. 2017 Aug 1;23(15):4462-4472. doi: 10.1158/1078-0432.CCR-16-2601. Epub 2017 Mar 7.

3.

PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

Srinivasan P, Wu X, Basu M, Rossi C, Sandler AD.

PLoS Med. 2018 Jan 29;15(1):e1002497. doi: 10.1371/journal.pmed.1002497. eCollection 2018 Jan.

4.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

5.

Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.

Smolle MA, Calin HN, Pichler M, Calin GA.

FEBS J. 2017 Jul;284(13):1952-1966. doi: 10.1111/febs.14030. Epub 2017 Feb 17. Review.

6.

Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.

Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel BR, Santi M, Merchant MS, Geoerger B, Hezam I, Marty V, Vielh P, Daugaard M, Sorensen PH, Mackall CL, Maris JM.

Cancer. 2017 Oct 1;123(19):3807-3815. doi: 10.1002/cncr.30724. Epub 2017 Jun 13.

7.
8.

Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.

Spurny C, Kailayangiri S, Jamitzky S, Altvater B, Wardelmann E, Dirksen U, Hardes J, Hartmann W, Rossig C.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26719. Epub 2017 Sep 4.

PMID:
28868758
9.

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.

Drakes ML, Mehrotra S, Aldulescu M, Potkul RK, Liu Y, Grisoli A, Joyce C, O'Brien TE, Stack MS, Stiff PJ.

J Ovarian Res. 2018 May 30;11(1):43. doi: 10.1186/s13048-018-0414-z.

10.

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C.

Oncotarget. 2017 Jul 4;8(27):44960-44975. doi: 10.18632/oncotarget.16680. Review.

11.

Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.

Barclay J, Creswell J, León J.

Arch Esp Urol. 2018 May;71(4):393-399. Review. Spanish, English.

PMID:
29745928
12.

MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.

Yee D, Shah KM, Coles MC, Sharp TV, Lagos D.

J Biol Chem. 2017 Dec 15;292(50):20683-20693. doi: 10.1074/jbc.M117.809053. Epub 2017 Oct 24.

13.

Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.

Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L, You Z.

Immunol Lett. 2017 Apr;184:7-14. doi: 10.1016/j.imlet.2017.02.006. Epub 2017 Feb 14.

14.

TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells.

Boes M, Meyer-Wentrup F.

Cancer Lett. 2015 May 28;361(1):49-56. doi: 10.1016/j.canlet.2015.02.027. Epub 2015 Feb 16.

PMID:
25697485
15.

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.

Wang J, Yuan R, Song W, Sun J, Liu D, Li Z.

J Hematol Oncol. 2017 Jan 25;10(1):34. doi: 10.1186/s13045-017-0403-5. Review.

16.

Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.

Nishijima TF, Shachar SS, Nyrop KA, Muss HB.

Oncologist. 2017 Apr;22(4):470-479. doi: 10.1634/theoncologist.2016-0419. Epub 2017 Mar 8. Review.

17.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R.

Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.

18.

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.

Brogden KA, Parashar D, Hallier AR, Braun T, Qian F, Rizvi NA, Bossler AD, Milhem MM, Chan TA, Abbasi T, Vali S.

BMC Cancer. 2018 Feb 27;18(1):225. doi: 10.1186/s12885-018-4134-y. Erratum in: BMC Cancer. 2018 Apr 12;18(1):413.

19.

[Regulation of PD-L1 by MicroRNA in Mismatch Repair Deficient-Colorectal Cancer].

Ashizawa M, Okayama H, Aung Kyi Thar Min, Noda M, Aoto K, Nakajima T, Ishigame T, Mimura K, Kono K.

Gan To Kagaku Ryoho. 2017 Oct;44(10):889-891. Japanese.

PMID:
29066686
20.

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.

Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.

J Clin Oncol. 2017 Dec 1;35(34):3867-3876. doi: 10.1200/JCO.2017.74.7642. Epub 2017 Oct 20. Review.

PMID:
29053400

Supplemental Content

Support Center